Urinary angiotensinogen levels in relation to renal involvement of Henoch-Schonlein purpura in children

Nephrology

Volumn 17, Issue 1, 2012, Pages 53-57

  Mao, Yan Na ^a   Liu, Wei ^b   Li, Yan Ge ^b   Jia, Guo Cun ^b   Zhang, Zhang ^b   Guan, Yu Jie ^b   Zhou, Xu Feng ^b   Liu, Yu Feng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU CHILDREN S HOSPITAL   (China)

Author keywords

Henoch Schonlein purpura; Henoch Schonlein purpura nephritis; proteinuria; renal involvement; urinary angiotensinogen

Indexed keywords

ANGIOTENSINOGEN; CREATININE; NITROGEN; UREA;

ANAPHYLACTOID PURPURA; ARTICLE; CASE CONTROL STUDY; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CONVALESCENCE; CREATININE URINE LEVEL; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATURIA; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SCHOOL CHILD; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ACUTE-PHASE REACTION; ANGIOTENSINOGEN; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CONVALESCENCE; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATURIA; HUMANS; KIDNEY; MALE; MONITORING, PHYSIOLOGIC; OUTCOME ASSESSMENT (HEALTH CARE); PROTEINURIA; PURPURA, SCHOENLEIN-HENOCH; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX;

EID: 84855175686     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01515.x     Document Type: Article

References (33)

1. Lau KK, Suzuki H, Novak J, et al,. Pathogenesis of Henoch-Schonlein purpura nephritis. Pediatr. Nephrol. 2010; 25: 19-26.
2. Reamy BV, Williams PM, Lindsay TJ,. Henoch-schonlein purpura. Am. Fam. Physician 2009; 80: 697-704.
3. Dixit MP, Dixit NM, Scott K,. Managing Henoch-Schonlein purpura in children with fish oil and ACE inhibitor therapy. Nephrology (Carlton) 2004; 9: 381-6. (Pubitemid 40115963)
4. Saulsbury FT,. Epidemiology of Henoch-Schonlein purpura. Cleve. Clin. J. Med. 2002; 69: 187-9.
5. Narchi H,. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch. Dis. Child. 2005; 90: 916-20. (Pubitemid 41232341)
6. Wilhelm-Bals A, Chehade H, Girardin E,. Henoch-Schönlein Purpura a dual follow up between pediatrician and pediatric nephrologist. Rev. Med. Suisse 2011; 7: 442-6.
7. Anderson PW, Do YS, Hsueh WA,. Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993; 21: 29-35. (Pubitemid 23006449)
8. Perico N, Zoja C, Corna D, et al,. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int. 2009; 76: 960-7.
9. Navar LG, Harrison-Bernard LM, Imig JD, et al,. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J. Am. Soc. Nephrol. 1999; 10: S266-272. (Pubitemid 29159460)
10. Del Prete D, Gambaro G, Lupo A, et al,. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int. 2003; 64: 149-59. (Pubitemid 36714167)
11. Kobori H, Ozawa Y, Suzaki Y, et al,. Young Scholars Award Lecture: Intratubular angiotensinogen in hypertension and kidney diseases. Am. J. Hypertens. 2006; 19: 541-50.
12. Kobori H, Ohashi N, Katsurada A, et al,. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J. Am. Soc. Hypertens 2008; 2: 349-54.
13. Singh R, Singh AK, Leehey DJ,. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am. J. Physiol. Renal Physiol. 2005; 288: F1183-F1190. (Pubitemid 40677088)
14. Kobori H, Ozawa Y, Suzaki Y, et al,. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J. Am. Soc. Nephrol. 2005; 16: 2073-80. (Pubitemid 41716438)
15. Mills JA, Michel BA, Bloch DA, et al,. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990; 33: 1114-21. (Pubitemid 20273296)
16. Qin YH, Zhou TB, Lei FY, et al,. Cut-off values for serum matrix metalloproteinase-9: is there a threshold to predict renal involvement for Henoch-Schonlein purpura in children? Nephrology (Carlton) 2011; 16: 93-9.
17. Tizard EJ,. Henoch-Schonlein purpura. Arch. Dis. Child. 1999; 80: 380-3. (Pubitemid 29164767)
18. Wong C, Kanetsky P, Raj D,. Genetic polymorphisms of the RAS-cytokine pathway and chronic kidney disease. Pediatr. Nephrol. 2008; 23: 1037-51.
19. Jacobsen P, Tarnow L, Carstensen B, et al,. Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J. Am. Soc. Nephrol. 2003; 14: 2843-50. (Pubitemid 37305647)
20. Kobori H, Ozawa Y, Satou R, et al,. Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in genetargeted mice. Am. J. Physiol. Renal Physiol. 2007; 293: F938-F945. (Pubitemid 47403366)
21. Yamamoto T, Nakagawa T, Suzuki H, et al,. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J. Am. Soc. Nephrol. 2007; 18: 1558-65. (Pubitemid 46717523)
22. Darby IA, Sernia C,. In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys. Cell Tissue Res. 1995; 281: 197-206.
23. Lantelme P, Rohrwasser A, Gociman B, et al,. Effects of dietary sodium and genetic background on angiotensinogen and renin in mouse. Hypertension 2002; 39: 1007-14. (Pubitemid 34547801)
24. Kobori H, Katsurada A, Ozawa Y, et al,. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem. Biophys. Res. Commun. 2007; 358: 156-63. (Pubitemid 46719097)
25. Takamatsu M, Urushihara M, Kondo S, et al,. Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy. Pediatr. Nephrol. 2008; 23: 1257-67.
26. Ferrario CM, Strawn WB,. Role of the renin-angiotensinaldosterone system and proinflammatory mediators in cardiovascular disease. Am. J. Cardiol. 2006; 98: 121-8. (Pubitemid 43902687)
27. Leung DY,. Immunologic aspects of Kawasaki syndrome. J. Rheumatol. Suppl. 1990; 24: 15-8. (Pubitemid 20321770)
28. Besbas N, Saatci U, Ruacan S, et al,. The role of cytokines in Henoch-Schonlein purpura. Scand. J. Rheumatol. 1997; 26: 456-60.
29. Ha TS,. The role of tumor necrosis factor-alpha in Henoch-Schonlein purpura. Pediatr. Nephrol. 2005; 20: 149-53.
30. Greenwood J, Heasman SJ, Alvarez JI, et al,. Review: leucocyte- endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol. Appl. Neurobiol. 2011; 37: 24-39.
31. Tomosugi NI, Cashman SJ, Hay H, et al,. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J. Immunol. 1989; 142: 3083-90. (Pubitemid 19129926)
32. Royall JA, Berkow RL, Beckman JS, et al,. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol. 1989; 257: 399-410.
33. Wang SX, Rastaldi MP, Patari A, et al,. Patterns of nephrin and a new proteinuria-associated protein expression in human renal diseases. Kidney Int. 2002; 61: 141-7. (Pubitemid 34075140)